ARA-290 is a synthetic peptide derived from the tertiary structure of erythropoietin. It was engineered to selectively activate the innate repair receptor (IRR), a receptor complex involved in tissue protection and inflammation control.
Unlike full-length erythropoietin, ARA-290:
Does not bind the classical erythropoietin receptor responsible for red blood cell production
Does not increase hematocrit
Does not stimulate bone marrow erythropoiesis
Instead, it selectively activates anti-inflammatory and cytoprotective pathways.
Cibinetide is the international nonproprietary name (INN) used in clinical research and pharmaceutical development. Both terms refer to the same molecule.
In scientific literature:
ARA-290 is commonly used in experimental and peptide discussions
Cibinetide is more frequently used in clinical trial publications
For clarity and consistency, both terms are often used interchangeably.
The innate repair receptor is a heteromeric receptor complex composed of:
Erythropoietin receptor (EPOR)
β-common receptor (CD131)
This receptor is activated in response to:
Chronic inflammation and neuropathy are frequently driven by upstream factors such as:
Gut barrier dysfunction
Dysbiosis
Metabolic stress
Peptides like BPC-157 and KPV are often discussed alongside ARA-290 because they address:
Intestinal permeability
Mucosal inflammation
Immune signaling at the gut level
By reducing inflammatory load, these strategies may enhance the effectiveness of neuroprotective peptides.
Nerve cells are highly dependent on mitochondrial function.
ARA-290 supports:
Mitochondrial integrity
Reduced oxidative stress
Improved cellular energy signaling
This makes it conceptually synergistic with mitochondrial-supportive interventions.
A key advantage of ARA-290 is that it promotes inflammation resolution, not blanket suppression.
Resolution involves:
Turning off inflammatory signaling once repair is complete
Preserving immune surveillance
Preventing chronic immune activation
This distinction is central to integrative approaches to chronic disease.
Clinical trials have demonstrated:
Excellent tolerability
No significant hematologic changes
No increased infection risk
No evidence of immunosuppression
Most adverse effects reported have been mild and transient.
Tissue injury
Hypoxia
Inflammation
Oxidative stress
Activation of the IRR triggers a cascade of protective signaling designed to:
Limit tissue damage
Reduce inflammation
Promote cellular survival
Support repair rather than scarring
ARA-290 was designed specifically to activate this receptor without activating erythropoiesis.
ARA-290 suppresses pro-inflammatory cytokines, including:
TNF-α
IL-1β
IL-6
It also inhibits NF-κB signaling, a central driver of chronic inflammation.
Importantly, this effect is immunomodulatory, not immunosuppressive, meaning it calms excessive inflammation without shutting down immune defense.
ARA-290 has been extensively studied for its effects on:
Small fiber neuropathy
Diabetic neuropathy
Chemotherapy-induced nerve damage
Autonomic dysfunction
Mechanisms include:
Reduced neuroinflammation
Improved mitochondrial function in neurons
Enhanced nerve fiber survival
Restoration of sensory signaling
In preclinical models, ARA-290 protects tissues exposed to:
Hypoxia
Ischemia-reperfusion injury
Oxidative stress
This has implications for:
Cardiovascular health
Kidney protection
Neurovascular integrity
ARA-290 improves endothelial signaling and reduces microvascular inflammation. This is particularly relevant in conditions characterized by:
Capillary dysfunction
Impaired tissue perfusion
Chronic inflammatory injury
